Summary & Overview
HCPCS Level II C9448: Netupitant 300 mg and Palonosetron 0.5 mg, Oral
HCPCS Level II code C9448 denotes a fixed-dose oral combination of netupitant 300 mg and palonosetron 0.5 mg, an antiemetic regimen used to prevent chemotherapy-induced nausea and vomiting. On a national scale, accurate coding for this oral oncology supportive care medication matters for claim adjudication, drug benefit management, and consistent patient access to guideline-directed antiemetic prophylaxis.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose and typical sites of service, national reimbursement and coverage benchmarks, common billing considerations, and recent policy updates affecting oral oncology supportive medications. The publication outlines differences in payer approaches to coverage criteria, site-of-service recognition (outpatient clinic vs. pharmacy benefit), and claim processing that can influence revenue cycle workflows.
The report provides practical benchmarks for utilization and reimbursement, a summary of payer policy trends, and the clinical context needed to align coding with oncology care pathways. Data not available in the input is flagged where applicable; the content focuses on nationally relevant policy and billing implications rather than state-specific rules.
Billing Code Overview
HCPCS Level II code C9448 represents netupitant 300 mg and palonosetron 0.5 mg, oral. This combination product is an antiemetic therapy used to prevent chemotherapy-induced nausea and vomiting.
-
Service type: Oral antiemetic drug administration
-
Typical site of service: Outpatient clinics, oncology infusion centers, and outpatient pharmacy dispensing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult oncology patient scheduled to receive moderately to highly emetogenic chemotherapy for which oral antiemetic prophylaxis with the fixed-dose combination of netupitant 300 mg and palonosetron 0.5 mg is planned. The patient presents to an outpatient oncology infusion clinic or an ambulatory infusion center on the day of chemotherapy. The oncology nurse verifies the chemotherapy regimen, reviews prior antiemetic response, allergies, and current medications (including serotoninergic agents and QT-prolonging drugs). The oral C9448 product is dispensed by the clinic pharmacy or brought by the patient, administered orally approximately 1 hour prior to chemotherapy start per product labeling, and documentation is recorded in the medical record: indication, dose, time of administration, lot number, and any adverse reactions. Follow-up includes monitoring for acute nausea/vomiting during infusion and delayed symptoms over the ensuing 5–7 days, with supportive medication orders provided as needed. Typical sites of service are outpatient oncology infusion centers, ambulatory clinics, and hospital outpatient departments; the service type is oral antiemetic pharmacologic prophylaxis for chemotherapy-induced nausea and vomiting (CINV).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
24 | Unrelated Evaluation and Management (E/M) service by the same physician during a postoperative period |